Masimo and Samsung Partner to Package Masimo SafetyNet™ with Select Samsung Phones to Speed COVID-19 Response Efforts
April 16 2020 - 6:09PM
Business Wire
Sensor-App-Phone Bundle Expected to Help
Expedite Deployment of Remote Patient Management Solution to
Patients Without Smartphones
Masimo (NASDAQ: MASI) announced today that it is partnering with
Samsung Electronics America to make the Masimo SafetyNet™ Patient
App available on select Samsung smartphones, pre-installed and
pre-configured. Masimo SafetyNet is an innovative, economically
scalable cloud-based patient management solution designed to help
clinicians care for patients remotely in hospital settings and in
non-traditional settings and circumstances. The partnership with
Samsung is expected to allow for broader, faster distribution of
Masimo SafetyNet to COVID-19 patients, especially older patients
who are less likely to own a smartphone or have the comfort level
to configure the Masimo SafetyNet App on their own.
Masimo’s telehealth platform uses a tetherless, wearable
single-patient-use SET® sensor to monitor a patient’s blood oxygen
saturation and pulse rate, as well as respiration rate, perfusion
index, and PVi®, and is designed to help manage the surge in
COVID-19 patients while maintaining distance from other patients
and providers, allowing hospitals to expand patient remote
monitoring into alternative care spaces, including overflow
locations, emergency recovery facilities, skilled nursing
facilities, and home care settings.
The telehealth solution combines clinically proven Masimo SET®
Measure-through Motion and Low Perfusion™ pulse oximetry with a
cloud-based remote data capture and surveillance platform
accessible from the patient’s Android or iOS smartphone or smart
device – or now, pre-installed on a Samsung Galaxy smartphone
provided alongside the tetherless sensors. Monitoring key
physiological data can help provide clinicians with an accurate
snapshot of a patient’s respiratory status and facilitates
awareness of the need for intervention.
Joe Kiani, Founder and CEO of Masimo, said, “Masimo SafetyNet is
helping to save lives by ensuring patients remain monitored from
afar even during quarantine. Older patients are at greater risk,
but are less likely to have smartphones. Samsung reached out to us,
wanting to help us with the pandemic. We are grateful for their
help in making it easier and faster for our much needed technology
to reach more of those patients who need remote monitoring and
management the most.”
Taher Behbehani, General Manager and Head of Mobile B2B for
Samsung Electronics America, added, “Today, remote care solutions
are more important than ever. We are proud to partner with Masimo
to provide the technology and solutions our communities need. Our
Galaxy smartphones with Knox security are fully equipped with the
necessary connectivity and security to allow Masimo monitoring data
to reach providers, safely and efficiently.”
For added simplification and ease of use, the Samsung phones
available alongside Masimo SafetyNet can be locked to provide only
Masimo SafetyNet functionality.
@MasimoInnovates | #Masimo
About Masimo
Masimo (NASDAQ: MASI) is a global medical technology company
that develops and produces a wide array of industry-leading
monitoring technologies, including innovative measurements,
sensors, patient monitors, and automation and connectivity
solutions. Our mission is to improve patient outcomes and reduce
the cost of care. Masimo SET® Measure-through Motion and Low
Perfusion™ pulse oximetry, introduced in 1995, has been shown in
over 100 independent and objective studies to outperform other
pulse oximetry technologies.1 Masimo SET® has also been shown to
help clinicians reduce severe retinopathy of prematurity in
neonates,2 improve CCHD screening in newborns,3 and, when used for
continuous monitoring with Masimo Patient SafetyNet™ in
post-surgical wards, reduce rapid response team activations, ICU
transfers, and costs.4-6 Masimo SET® is estimated to be used on
more than 200 million patients in leading hospitals and other
healthcare settings around the world,7 and is the primary pulse
oximetry at 9 of the top 10 hospitals listed in the 2019-20 U.S.
News and World Report Best Hospitals Honor Roll.8 Masimo continues
to refine SET® and in 2018, announced that SpO2 accuracy on RD SET®
sensors during conditions of motion has been significantly
improved, providing clinicians with even greater confidence that
the SpO2 values they rely on accurately reflect a patient’s
physiological status. In 2005, Masimo introduced rainbow® Pulse
CO-Oximetry technology, allowing noninvasive and continuous
monitoring of blood constituents that previously could only be
measured invasively, including total hemoglobin (SpHb®), oxygen
content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®),
Pleth Variability Index (PVi®), RPVi™ (rainbow® PVi), and Oxygen
Reserve Index (ORi™). In 2013, Masimo introduced the Root® Patient
Monitoring and Connectivity Platform, built from the ground up to
be as flexible and expandable as possible to facilitate the
addition of other Masimo and third-party monitoring technologies;
key Masimo additions include Next Generation SedLine® Brain
Function Monitoring, O3® Regional Oximetry, and ISA™ Capnography
with NomoLine® sampling lines. Masimo’s family of continuous and
spot-check monitoring Pulse CO-Oximeters® includes devices designed
for use in a variety of clinical and non-clinical scenarios,
including tetherless, wearable technology, such as Radius-7® and
Radius PPG™, portable devices like Rad-67™, fingertip pulse
oximeters like MightySat® Rx, and devices available for use both in
the hospital and at home, such as Rad-97®. Masimo hospital
automation and connectivity solutions are centered around the Iris®
platform, and include Iris Gateway®, Patient SafetyNet, Replica™,
Halo ION™, UniView™, and Masimo SafetyNet™. Additional information
about Masimo and its products may be found at www.masimo.com.
Published clinical studies on Masimo products can be found at
www.masimo.com/evidence/featured-studies/feature/.
ORi and RPVi have not received FDA 510(k) clearance and are not
available for sale in the United States. The use of the trademark
Patient SafetyNet is under license from University HealthSystem
Consortium.
References
- Published clinical studies on pulse oximetry and the benefits
of Masimo SET® can be found on our website at
http://www.masimo.com. Comparative studies include independent and
objective studies which are comprised of abstracts presented at
scientific meetings and peer-reviewed journal articles.
- Taenzer AH et al. Impact of pulse oximetry surveillance on
rescue events and intensive care unit transfers: a before-and-after
concurrence study. Anesthesiology. 2010:112(2):282-287.
- Taenzer A et al. Postoperative Monitoring – The Dartmouth
Experience. Anesthesia Patient Safety Foundation Newsletter.
Spring-Summer 2012.
- McGrath SP et al. Surveillance Monitoring Management for
General Care Units: Strategy, Design, and Implementation. The Joint
Commission Journal on Quality and Patient Safety. 2016
Jul;42(7):293-302.
- Castillo A et al. Prevention of Retinopathy of Prematurity in
Preterm Infants through Changes in Clinical Practice and SpO2
Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
- de-Wahl Granelli A et al. Impact of pulse oximetry screening on
the detection of duct dependent congenital heart disease: a Swedish
prospective screening study in 39,821 newborns. BMJ. 2009;Jan
8;338.
- Estimate: Masimo data on file.
-
http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.
Forward-Looking Statements
This press release includes forward-looking statements as
defined in Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, in connection with the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, among others, statements
regarding the potential effectiveness of Masimo SafetyNet™ and
SET®. These forward-looking statements are based on current
expectations about future events affecting us and are subject to
risks and uncertainties, all of which are difficult to predict and
many of which are beyond our control and could cause our actual
results to differ materially and adversely from those expressed in
our forward-looking statements as a result of various risk factors,
including, but not limited to: risks related to our assumptions
regarding the repeatability of clinical results; risks related to
our belief that Masimo's unique noninvasive measurement
technologies, including Masimo SafetyNet and SET®, contribute to
positive clinical outcomes and patient safety; risks related to our
belief that Masimo noninvasive medical breakthroughs provide
cost-effective solutions and unique advantages; risks related to
COVID-19; as well as other factors discussed in the "Risk Factors"
section of our most recent reports filed with the Securities and
Exchange Commission ("SEC"), which may be obtained for free at the
SEC's website at www.sec.gov. Although we believe that the
expectations reflected in our forward-looking statements are
reasonable, we do not know whether our expectations will prove
correct. All forward-looking statements included in this press
release are expressly qualified in their entirety by the foregoing
cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of today's date. We do not undertake any obligation to update,
amend or clarify these statements or the "Risk Factors" contained
in our most recent reports filed with the SEC, whether as a result
of new information, future events or otherwise, except as may be
required under the applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200416005990/en/
Masimo Evan Lamb 949-396-3376 elamb@masimo.com
Masimo (NASDAQ:MASI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Masimo (NASDAQ:MASI)
Historical Stock Chart
From Apr 2023 to Apr 2024